A large genetic study has uncovered an unexpected connection between irritable bowel syndrome (IBS) and elevated triglyceride levels, suggesting the condition involves the body's metabolic system far more than previously understood. Researchers analyzing data from nearly 2.8 million individuals across 22 international biobanks discovered that IBS shares genetic pathways with cardiometabolic traits, opening new avenues for treatment and patient care.

What Does This Discovery Mean for IBS Patients?

IBS affects between 5% and 15% of the general population and is more common in women, significantly reducing quality of life for millions. The condition has long been understood as a disorder of gut-brain interaction, but researchers have struggled to develop effective treatments because the underlying mechanisms remained unclear. This new research suggests the picture is far more complex than the traditional gut-brain axis model.

The study identified 35 regions of the human genome associated with IBS risk. While several involved the brain and enteric nervous system (the nervous system controlling the digestive tract), researchers were surprised to find a strong overlap with cardiometabolic traits. Most notably, they demonstrated a likely causal link between genetic liability for IBS and elevated blood triglycerides, which was not explained by body weight.

"This association of IBS with pro-atherogenic lipid profiles is consistent with large-scale observational studies that have repeatedly documented a strong link between IBS and metabolic syndrome, including cardiovascular traits and elevated triglycerides, but not BMI," the researchers wrote in their findings.

Study authors, published in Gut

How Does This Genetic Link Work?

The molecular basis for the connection centers on a single genetic variant in the gene for glucokinase regulatory protein (GKRP), which regulates triglyceride metabolism. This same variant is associated with metabolic dysfunction-associated fatty liver disease, suggesting a shared metabolic background between IBS and liver function.

"We have long known that IBS involves a complex dialogue between the gut and the brain, but these results show that the conversation includes the body's metabolic system too. The genetic link to triglyceride regulation and liver function gives us a completely new framework for understanding the condition," explained Mauro D'Amato, PhD, professor of medical genetics at LUM University in Bari, Italy, and Ikerbasque research professor at CIC bioGUNE in Bilbao, Spain.

Mauro D'Amato, PhD, Professor of Medical Genetics at LUM University

This discovery fundamentally shifts how researchers think about IBS. Rather than viewing it as purely a gut or neurological condition, the evidence suggests metabolic dysfunction plays a central role. Understanding this connection could help doctors identify which patients are at higher risk for both IBS and cardiovascular complications.

What New Treatment Options Could This Lead To?

The research team identified 276 chemical agents with possible therapeutic relevance for IBS, of which 156 had a defined mechanism of action. These potential treatments fall into several categories:

• Existing IBS medications: Compounds already used off-label for IBS symptoms, including nortriptyline, sertraline, lorazepam, curcumin, and capsaicin
• Cardiovascular drugs: Medications typically used to treat heart and blood pressure conditions, such as urapidil, fenoldopam, indapamide, nicardipine, picotamide, and torsemide
• Triglyceride-modifying compounds: Drugs that lower blood fat levels, including rosuvastatin and simvastatin
• Novel opportunities: 120 small molecules without a known target or mechanism of action that could represent entirely new treatment approaches

The researchers emphasize that the remaining 120 compounds without established mechanisms "could represent potential novel opportunities for translational research in IBS." This suggests that future treatments might target the metabolic dysfunction underlying the condition rather than simply managing symptoms.

"Our findings support a more integrated view of IBS that extends beyond the traditional gut-brain axis. The specific pathways we highlighted may contribute to mechanism-based patient stratifications and the identification of new or existing drugs to be tested in patients who do not respond to current therapies," noted Mauro D'Amato.

Mauro D'Amato, PhD, Professor of Medical Genetics at LUM University

Why Does This Matter for Your Health?

The implications of this research extend beyond IBS treatment alone. People with IBS who also have elevated triglycerides may face increased cardiovascular risk, a connection that has been documented in large observational studies but not fully understood at the genetic level. This discovery provides a biological explanation for why IBS patients sometimes develop metabolic syndrome, a cluster of conditions including high blood pressure, high blood sugar, excess body fat, and abnormal cholesterol levels.

Additionally, the research highlights the importance of screening IBS patients for metabolic risk factors. Doctors may now consider checking triglyceride levels and liver function in patients with IBS, particularly those with a family history of cardiovascular disease or metabolic disorders. Understanding the genetic overlap could also help identify which patients might benefit from specific medications that address both gut symptoms and metabolic dysfunction.

The study represents what researchers describe as "the most comprehensive assessment to date of IBS genetic architecture, its subtypes, and the biological and translational inferences that can be drawn from common-variant association signals." As researchers continue to investigate these metabolic pathways, patients with IBS may soon have access to more targeted, mechanism-based treatments tailored to their individual genetic profiles.